Fiche société
University of Florence
Traitements, essais et publications liés.
Traitements14programmes
Essais10liés
Publications14liées
SourceDBlocale
Traitements
14| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Eptinezumab 100 or 300 mg evThe purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients. | Migraine | À vérifier | À vérifier | Italy | À vérifier |
| LasmiditanThe purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation. | Migraine | À vérifier | À vérifier | Italy | À vérifier |
| Rimegepant 75 MGIn a real-world population of adults with migraine, the investigators would like to investigate whether 50 mg diclofenac potassium is non-inferior to 75 mg rimegepant in terms of pain freedom at 2 hours after drug intake. | Migraine | À vérifier | Traitement symptomatique | Italy | À vérifier |
| Rimegepant 75 MG Disintegrating Oral TabletThe purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients. | Migraine | À vérifier | À vérifier | Italy | À vérifier |
| Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control TherapyChronic migraine is a disabling type of migraine and is often resistant to treatment. Non-pharmacological interventions have been investigated as potential treatment although, unfortunately, the literature on their efficacy is poor and showed mixed results. Well-Being Therapy (WBT) is a brief psychotherapy which has shown efficacy in decreasing the relapse rates of depression in adults, in generalized anxiety disorder and in cyclothymia. It can be implemented to empower psychological well-being. The aim of the present study is to test the efficacy of WBT in a sample of patients with chronic migraine to verify if it reduces the disability due to migraine and distress, it increases the psychological well-being as well as the level of euthymia. | Migraine | Non applicable | À vérifier | Italy | À vérifier |
| LasmiditanThe purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation. | Migraine | Phase 2 | À vérifier | Belgium, Finland, France, Germany, Spain | À vérifier |
| LasmiditanThe purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation. | Migraine | À vérifier | À vérifier | Italy | À vérifier |
| Eptinezumab 100 or 300 mg evThe purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients. | Migraine | À vérifier | À vérifier | Italy | À vérifier |
| Rimegepant 75 MGIn a real-world population of adults with migraine, the investigators would like to investigate whether 50 mg diclofenac potassium is non-inferior to 75 mg rimegepant in terms of pain freedom at 2 hours after drug intake. | Migraine | À vérifier | Traitement symptomatique | Italy | À vérifier |
| Rimegepant 75 MG Disintegrating Oral TabletThe purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients. | Migraine | À vérifier | À vérifier | Italy | À vérifier |
| Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control TherapyChronic migraine is a disabling type of migraine and is often resistant to treatment. Non-pharmacological interventions have been investigated as potential treatment although, unfortunately, the literature on their efficacy is poor and showed mixed results. Well-Being Therapy (WBT) is a brief psychotherapy which has shown efficacy in decreasing the relapse rates of depression in adults, in generalized anxiety disorder and in cyclothymia. It can be implemented to empower psychological well-being. The aim of the present study is to test the efficacy of WBT in a sample of patients with chronic migraine to verify if it reduces the disability due to migraine and distress, it increases the psychological well-being as well as the level of euthymia. | Migraine | Non applicable | À vérifier | Italy | À vérifier |
| LasmiditanThe purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation. | Migraine | Phase 3 | À vérifier | United States, Belgium, Canada, France, Germany, India, Italy, Japan, Mexico, Netherlands, Puerto Rico, Romania, Russia, Spain, United Kingdom | À vérifier |
| LasmiditanThe purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation. | Migraine | Phase 2 | À vérifier | Japan | À vérifier |
| LasmiditanThe purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation. | Migraine | Phase 3 | À vérifier | United States, Belgium, Canada, France, Germany, India, Italy, Japan, Mexico, Netherlands, Puerto Rico, Romania, Russia, Spain, United Kingdom | À vérifier |
Essais cliniques
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Lasmiditan | Migraine | Phase 3 | NCT04396236 | PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Lasmiditan | Migraine | Phase 2 | NCT03962738 | MONONOFU — A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine | COMPLETED |
| Lasmiditan | Migraine | Phase 3 | NCT04396574 | PIONEER-PEDS2 — A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy | Migraine | Non applicable | NCT03404336 | Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy | RECRUITING |
| Atogepant 60 mg | Migraine | À vérifier | NCT06414044 | STAR — Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients | ACTIVE_NOT_RECRUITING |
| Rimegepant 75 MG Disintegrating Oral Tablet | Migraine | À vérifier | NCT05903027 | Gepant treAtments: EffectIveNess and tolERability (GAINER) | RECRUITING |
| Rimegepant 75 MG | Migraine | À vérifier | NCT06409832 | RAISE — RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment | RECRUITING |
| Eptinezumab 100 or 300 mg ev | Migraine | À vérifier | NCT06409845 | TACHIS — Effectiveness and Tolerability of Eptinezumab | COMPLETED |
| Lasmiditan | Migraine | À vérifier | NCT05903040 | Ditan Acute tReatments: Effectiveness and Tolerability (DART) | COMPLETED |
| Lasmiditan | Migraine | Phase 2 | NCT00883051 | Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment | COMPLETED |
Publications
14| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy | Zhenwu Decoction ameliorates experimental benign prostatic hyperplasia: association with mitochondrial quality control, oxidative stress and apoptosis regulation. | Journal of ethnopharmacology | ||
| Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy | 1-Deoxynojirimycin attenuates diabetic cardiomyopathy via PI3K/AKT-mediated mitochondrial protection and anti-apoptosis. | Journal of ethnopharmacology | ||
| Rimegepant 75 MG Disintegrating Oral Tablet | Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With Migraine. | Clinical and translational science | ||
| Rimegepant 75 MG Disintegrating Oral Tablet | A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications. | Cephalalgia : an international journal of headache | ||
| Rimegepant 75 MG Disintegrating Oral Tablet | Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial. | PloS one | ||
| Eptinezumab 100 or 300 mg ev | Cobalt-induced charge redistribution and lattice distortion enable accelerated sodium storage kinetics in NASICON-type NaV(PO). | Journal of colloid and interface science | ||
| Eptinezumab 100 or 300 mg ev | Integrated multispectroscopic and DFT analysis of molecular heterogeneity in Garabagh asphaltenes (Azerbaijan). | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy | ||
| Eptinezumab 100 or 300 mg ev | High-temperature reversible emission in a simple Schiff base: activated quenching, exciton-phonon renormalization, and tautomer-driven spectral evolution. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy | ||
| Lasmiditan | Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan. | Neurology and therapy | ||
| Rimegepant 75 MG | Efficacy and safety of gepants in migraine management: a narrative review focusing on atogepant and rimegepant. | Journal of oral & facial pain and headache | ||
| Lasmiditan | Innovation is not enough: lessons from lasmiditan for real-world effectiveness in acute migraine therapy. | Expert review of neurotherapeutics | ||
| Lasmiditan | Regulation of mitochondrial biogenesis by the 5-HT1F receptor and its agonist in inferior spinal cords after spinal cord injury. | Neuroscience letters | ||
| Rimegepant 75 MG | Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study. | Frontiers in neurology | ||
| Rimegepant 75 MG | Effectiveness and clinical predictors of rimegepant for acute vertigo in vestibular migraine: A real-world cohort study. | Cephalalgia : an international journal of headache |